Edwards Lifesciences Trading Volume Surges 74.97% to 184th Position as Boston Scientific Exits TAVR Market

Generated by AI AgentAinvest Volume Radar
Wednesday, May 28, 2025 8:06 pm ET1min read

On May 28, 2025,

(EW) saw a significant increase in trading volume, with a turnover of 4.66 billion, marking a 74.97% rise from the previous day. This surge placed Edwards Lifesciences at the 184th position in terms of trading volume for the day. The stock price of Edwards Lifesciences rose by 0.58%, marking the third consecutive day of gains, with a total increase of 2.50% over the past three days.

Edwards Lifesciences' stock price surged on Wednesday following an announcement by Boston Scientific that it would cease selling its competing heart-valve replacement systems. This decision by Boston Scientific to discontinue the sales of its Acurate Neo and Acurate Neo2 transcatheter aortic valve replacement (TAVR) systems globally has provided a significant boost to Edwards Lifesciences' market position.

This strategic move by Boston Scientific is expected to have a positive impact on Edwards Lifesciences' market share, as it eliminates a key competitor in the TAVR market. The discontinuation of these products by Boston Scientific is likely to benefit Edwards Lifesciences, as it reduces competition and allows the company to capture a larger portion of the market.

Aime Insights

Aime Insights

How can investors capitalize on the historic rally in gold and silver?

How might the gold and silver rally in 2025 impact the precious metals sector?

What are the strategic implications of gold outperforming Bitcoin in 2025?

How might XRP's current price consolidation near $1.92 be influenced by recent ETF inflows and market sentiment?

Comments



Add a public comment...
No comments

No comments yet